Cross-over to JYP0322
Phase 3Small molecule
Cross-over to JYP0322 is one of 50 small molecule programs targeting Chemotherapy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
104 competitors in Chemotherapy
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Eloxatin
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Avastin
RochePhase 3
Cytosar
TevaPhase 3
Vepesid
AAvyxa
Phase 3
Imfinzi
AstraZenecaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Gemzar
Johnson & JohnsonPhase 3
Beyfortus
BeiGenePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cross-over to JYP0322. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- GGuangzhou JOYO Pharma Co., Ltd